

Poster presentation

## **Efficacy and tolerance of combination of maraviroc with MK-0518, boosted TMC-114, TMC-125, in heavily pre-treated CCR5-positive patients**

F Almasi\*, A Krivine, A Compangocci, B Silberman, L Belaebi and D Salmon

Address: Cochin Hospital, Paris, France

\* Corresponding author

from Ninth International Congress on Drug Therapy in HIV Infection  
Glasgow, UK. 9–13 November 2008

Published: 10 November 2008

*Journal of the International AIDS Society* 2008, **11**(Suppl 1):P46 doi:10.1186/1758-2652-11-S1-P46

This abstract is available from: <http://www.jiasociety.org/content/11/S1/P46>

© 2008 Almasi et al; licensee BioMed Central Ltd.

### **Background**

An important problem in treatment-experienced HIV-positive patients is resistance. It could be difficult to find a suitable regimen for heavily pre-treated patients.

### **Methods**

In heavily pre-treated patients in whom we found detectable viral load under adjusted antiretroviral treatment, according to result of resistance and tropism test, we tried a new therapeutic line as combination: MK-0518 + boosted TMC-114 + TMC-125 and maraviroc (all patients were naive to this combination). We measured viral load (Abbot Real time) (<40 copies/ml = undetectable) and CD4 count at day 1, week 3, week 8, week 12 and week 24.

### **Summary of results**

Among six patients who received this combination there are three men and three women. Mean age is 48.7 years ( $r = 46-50$ ). They have already received 8–19 therapeutic lines (mean = 11), as well as 11–18 (mean = 14) molecules. Mean viral load at day 1 was 35,638 copies/ml = 4.55 log( $r = 80-87,100$ ) which is reduced to 76 copies/ml = 1.88 log at week 3, 166 copies/ml = 2.22 log at week 8 and less than 40 copies/ml = 1.6 log = undetectable at week 12. At week 3, 3/6 patients found undetectable viral load and at week 8, 5/6 found undetectable viral load and at week 12 all six patients in therapeutic failure found undetectable viral load. CD4 count, which was 330 ( $r = 155-649$ ) at day 1, increased to 390 at week 3 and 394 at

week 8. We did not find any adverse events in this group of patients.

### **Conclusion**

Combination of TMC-114/R, TMC-125, MK-0518 and maraviroc can be a safe, good option in heavily pre-treated CCR5-positive patients which can reduce viral load 3–4 logs in 3 weeks and reach to undetectable viral load in less than 12 weeks.